NanoBio Corporation announced today that a sixth U.S. patent covering its novel nanoemulsion technology has been awarded. The patent encompasses composition of matter claims for the company's lead anti-infective and vaccine product candidates.
"We are very pleased with this patent award in that the new claims circumscribe all of NanoBio's anti-infective and dermatological products, as well as our intranasal and intramuscular vaccine adjuvants," said James R. Baker, Jr., MD, NanoBio's CEO and founder. "The timing of this allowance coincides nicely with several very important development milestones at NanoBio."
In December 2009, NanoBio and GlaxoSmithKline plc (GSK) announced an exclusive licensing agreement in the United States and Canada for the over-the-counter use of NB-001, NanoBio's lead product for the treatment of herpes labialis (cold sores). NanoBio is currently preparing to study the efficacy and safety of 0.3% NB-001 in two Phase 3 trials.
In addition, NanoBio's lead vaccine candidate, NB-1008, a seasonal influenza vaccine administered via a nasal dropper, has shown very promising results in a recently completed Phase 1 clinical study. The company is currently in partnership discussions with several parties regarding NB-1008.
The development of the nanoemulsion platform began in the 1990s at the University of Michigan, and has since been supported by over $110 million in grants, investments and partnership funding. The newly issued patent (U.S. #7,655,252) is licensed from the University of Michigan to NanoBio Corp. on an exclusive, worldwide basis. With this new patent, NanoBio now holds six U.S. patents and has filed over 30 additional applications.